Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 54 EUR -1.1% Market Closed
Market Cap: 522.7m EUR
Have any thoughts about
Pharmanutra SpA?
Write Note

Gross Margin
Pharmanutra SpA

95.6%
Current
97%
Average
31.7%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
95.6%
=
Gross Profit
150.9m
/
Revenue
157.8m

Gross Margin Across Competitors

Country IT
Market Cap 518.8m EUR
Gross Margin
96%
Country FR
Market Cap 181.7B EUR
Gross Margin
74%
Country UK
Market Cap 114.1B GBP
Gross Margin
0%
Country IN
Market Cap 5.5T INR
Gross Margin
52%
Country UK
Market Cap 34.9B GBP
Gross Margin
62%
Country DE
Market Cap 27.8B EUR
Gross Margin
58%
Country US
Market Cap 27B USD
Gross Margin
72%
Country JP
Market Cap 3T JPY
Gross Margin
38%
Country IN
Market Cap 1.1T INR
Gross Margin
56%
Country IN
Market Cap 903.7B INR
Gross Margin
49%
Country US
Market Cap 9.9B USD
Gross Margin
35%
No Stocks Found

Pharmanutra SpA
Glance View

Market Cap
518.8m EUR
Industry
Consumer products

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

PHN Intrinsic Value
42.67 EUR
Overvaluation 21%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
95.6%
=
Gross Profit
150.9m
/
Revenue
157.8m
What is the Gross Margin of Pharmanutra SpA?

Based on Pharmanutra SpA's most recent financial statements, the company has Gross Margin of 95.6%.